Trial Tests Whether Daily Calorie Restriction Can Slow Polycystic Kidney Growth
A 120-person trial is testing calorie restriction for inherited polycystic kidney disease. This protocol reports baseline data, not treatment benefits.
Summary
Researchers are testing whether daily calorie restriction can slow kidney enlargement in adults with autosomal dominant polycystic kidney disease, an inherited condition that causes kidney cysts. The trial enrolled 120 adults with overweight or obesity and assigned them to either a behavioral weight loss program or standard dietary advice for two years. MRI scans will track changes in kidney size relative to height. Participants averaged 45 years old; 84 were women and 36 were men. This paper reports the study plan and starting characteristics, not whether the intervention works. Completion of the final study cohort is expected in July 2027. The research could inform dietary management, but it does not yet justify calorie restriction as a treatment for kidney cyst growth. This summary is based only on the abstract.
Detailed Summary
Can sustained calorie reduction slow kidney enlargement in adults with inherited polycystic kidney disease? Researchers are testing that question in a randomized trial involving adults with overweight or obesity. The rationale combines evidence of altered metabolism in this disease with animal studies and preliminary human research suggesting that losing excess weight might help limit kidney growth.
The trial enrolled 120 adults with autosomal dominant polycystic kidney disease, known as ADPKD, at one research site. Participants were assigned to either a daily calorie restriction program with behavioral weight loss support or standard dietary advice for ADPKD. Treatment lasts 24 months. Investigators assessing outcomes are blinded to group assignment. The main outcome is change in total kidney volume, adjusted for height, measured using MRI.
This publication describes the protocol and starting characteristics, not treatment results. Participants included 84 women and 36 men, with an average age of 45 years. Average estimated kidney filtration was 68 milliliters per minute per 1.73 square meters. Median kidney volume adjusted for height was 986 milliliters per meter. Twenty-nine participants, or 24%, were taking tolvaptan at enrollment.
The study could clarify whether structured weight loss offers an additional approach to managing ADPKD in adults carrying excess weight. However, it does not yet establish that calorie restriction reduces kidney growth, preserves kidney function, or improves survival. Patients should discuss dietary changes with their kidney care team rather than replace established treatment with an unproven calorie restriction regimen.
Important limitations include the single study site and limited demographic diversity: 93% of participants were non-Hispanic White. The findings may not generalize to adults without overweight or obesity. Kidney volume is the primary outcome, rather than kidney failure or lifespan. Final cohort completion is expected in July 2027. This summary relies on the abstract only; detailed methods and results were unavailable.
Key Findings
- The trial randomized 120 adults with ADPKD and overweight or obesity to daily calorie restriction or standard dietary advice for 24 months.
- The primary outcome is MRI-measured change in total kidney volume adjusted for height, not lifespan or kidney failure.
- Participants averaged 45 years old; 84 were women, 36 were men, and 24% used tolvaptan at baseline.
- No treatment outcomes are reported; completion of the final study cohort is expected in July 2027.
- Discuss weight loss plans with a kidney care team; this protocol does not establish calorie restriction as an effective ADPKD treatment.
Methodology
This single-site, phase 2, randomized, investigator-blinded, parallel-group trial enrolled 120 adults with ADPKD and overweight or obesity. It compares a 24-month behavioral weight loss intervention based on daily calorie restriction with standard ADPKD dietary advice, using MRI-measured change in height-adjusted total kidney volume as the primary outcome. The trial is registered as NCT04907799.
Study Limitations
This summary is based on the abstract only, which reports the protocol and baseline characteristics rather than intervention outcomes or safety results. The single-site sample was 93% non-Hispanic White and included only adults with overweight or obesity, limiting generalizability. The primary endpoint measures kidney enlargement rather than kidney failure, survival, or healthspan.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: